Pelthos Therapeutics Inc. (PTHS)
AMEX AMEX Primary Summary
Pelthos Therapeutics Q2 Earnings Call Highlights
Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed an accounting restatement related to the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment's third full quarter since launch, executives said on the company's 2026 first-quarter earnings call.
Pelthos Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Li Peng China Universal Asset Management Co. Ltd. | 2,160 | $57,585.6 | $61,905.6 | $4,320 | 7.5% |
 Christopher C. Powers Farther Finance Advisors, LLC | 40 | $852 | $1,146.4 | $294.4 | 34.55% |
 Zachary Canonico DIADEMA PARTNERS LP | 24,773 | $737,150 | $681,257.5 | -$55,892.5 | -7.58% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 6,007 | $179,008 | $172,100.55 | -$6,907.45 | -3.86% |
Pelthos Therapeutics Inc. (PTHS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pelthos Therapeutics Inc. ever had a stock split?
Pelthos Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Scott Plesha CEO | AMEX Exchange | 171126204 CUSIP |
| US Country | 92 Employees | - Last Dividend | 2 Jul 2025 Last Split | - IPO Date |
Overview
Pelthos Therapeutics Inc. is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapeutic products aimed at addressing significant unmet medical needs. Founded in 2002, the company has established its headquarters in Durham, North Carolina. Initially known as Channel Therapeutics Corporation, it underwent a rebranding in July 2025 to become Pelthos Therapeutics Inc. The organization focuses on creating cutting-edge solutions to improve the quality of life for patients burdened by various medical conditions.
Products and Services
- ZELSUVMI
ZELSUVMI is a therapeutic product developed by Pelthos Therapeutics for the treatment of molluscum contagiosum, a viral skin infection that can affect both adults and children aged 1 year and older. This treatment aims to alleviate the physical and psychological discomfort associated with the condition by effectively targeting the underlying virus and promoting skin healing.
- NITRICIL
NITRICIL is a proprietary technology platform based on nitric oxide, which has a range of potential therapeutic applications. This innovative solution is designed to harness the unique properties of nitric oxide to develop treatments that may enhance the body's natural healing processes. The platform holds promise in various areas, aiming to provide effective options for patients facing challenging health conditions.
